×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

KATHERINE MALMO
A greater understanding of the cardiac side effects of cancer treatments has led to the formation of cardio-oncology teams.
Brielle Urciuoli
Using next-generation sequencing (NGS) to test patients with non-small cell lung cancer (NSCLC) for all known genetic mutations associated with the disease appeared to be faster and more cost-effective than testing for one gene at a time – not to mention the results could have treatment implications.
Jason M. Broderick
The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor. 
MIKE HENNESSY, SR.
Immunotherapy revolutionized the way we treat cancer. And now, researchers are using drugs to help jumpstart the immune system alongside chemotherapy to keep treatment moving forward.
 
DEBU TRIPATHY, M.D.
Lung cancer has gone from being a dismal diagnosis — it still is very serious — to one that is the poster child for targeted therapeutics, immunotherapy and molecular diagnostics. These advancements are just the beginning.
KATIE BROWN, OPN-CG
Unique challenges become permanent fixtures in the minds of young adults who receive a diagnosis of a life-changing disease, but can change through advocacy support.
Katie Kosko
During National Women’s Lung Health Week, a lung cancer survivor shares her story and success with targeted therapy.
Jason M. Broderick
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) to be used in combination with Avastin (bevacizumab), carboplatin and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).
MEERI KIM, PH.D.
Second cancers are common among patients with lung cancer, so how can risk be lowered?
ARLENE WEINTRAUB
Immune and targeted therapies build hope for patients with advanced lung cancer.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable